Review Article
Matthias Gorenflo, Siegrun
Abstract
Although substantial advances have been made in our understanding of pulmonary hypertensive vascular disease there remain important challenges to overcome in designing pediatric drug trials and improving long term survival. We address the current classifications and review the current knowledge on epidemiology, pathogenesis and therapy of pulmonary hypertension.